Incyte (INCY) Cash from Operations (2010 - 2026)
Incyte (INCY) reported Cash from Operations of 369351000.0 for Q1 2026, up 38.82% on a YoY basis from 266067000.0 in Q1 2025, and down 32.02% quarter-over-quarter from 543301000.0 in Q4 2025.
Incyte (INCY) Cash from Operations (2010 - 2026) Analysis & Trends
Incyte has reported Cash from Operations for 17 years, with the latest figure at 369351000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 38.82% year-over-year to 369351000.0; the trailing twelve-month figure through Mar 2026 stood at 1516782000.0 (up 296.45% YoY), and the FY2025 full-year result was 1413498000.0, up 321.52% from the prior year.
- Cash from Operations for Q1 2026 stood at 369351000.0, down from 543301000.0 in the prior quarter.
- The five-year high for Cash from Operations was 559389000.0 in Q3 2025, with the low at 575563000.0 in Q2 2024.
- Historically, Cash from Operations has averaged 210859647.06 across 5 years, with a median of 266067000.0 in 2025.
- The largest YoY upside for Cash from Operations was 307.2% in 2024 against a maximum downside of 287.77% in 2024.
- Incyte's Cash from Operations stood at 283662000.0 in 2022, then slumped by 47.92% to 147729000.0 in 2023, then surged by 158.05% to 381218000.0 in 2024, then surged by 42.52% to 543301000.0 in 2025, then sank by 32.02% to 369351000.0 in 2026.
- The last three Cash from Operations figures came in at 369351000.0 (Q1 2026), 543301000.0 (Q4 2025), and 559389000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 369.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369.35 Mn |
| Mar 31, 2026 | 369.35 Mn |
| Dec 31, 2025 | 543.30 Mn |
| Dec 31, 2025 | 543.30 Mn |
| Sep 30, 2025 | 559.39 Mn |
| Sep 30, 2025 | 559.39 Mn |
| Jun 30, 2025 | 44.74 Mn |
| Jun 30, 2025 | 44.74 Mn |
| Mar 31, 2025 | 266.07 Mn |
| Mar 31, 2025 | 266.07 Mn |
| Dec 31, 2024 | 381.22 Mn |
| Dec 31, 2024 | 381.22 Mn |
| Sep 30, 2024 | 310.87 Mn |
| Sep 30, 2024 | 310.87 Mn |
| Jun 30, 2024 | -575.56 Mn |
| Jun 30, 2024 | -575.56 Mn |
| Mar 31, 2024 | 218.81 Mn |
| Mar 31, 2024 | 218.81 Mn |
| Dec 31, 2023 | 147.73 Mn |
| Dec 31, 2023 | 147.73 Mn |